

## Bringing the Patient into the Equation: A Pilot CME Initiative on the Treatment of Acute Myeloid Leukemia — Issue 1

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The combination of venetoclax and azacitidine is effective in which of the following chemotherapy-ineligible patients with previously untreated acute myeloid leukemia (AML)?
  - a. Patients with FLT3 mutations only
  - b. Patients with IDH1/2 mutations only
  - c. Patients with either FLT3 or IDH1/2 mutations
2. Which of the following drug types best describes the mechanism of action of gilteritinib?
  - a. Bcl-2 inhibitor
  - b. IDH1/2 inhibitor
  - c. FLT3 inhibitor
3. Which of the following statements is FALSE regarding the SRSF2 mutation in patients with AML?
  - a. This mutation affects the spliceosome
  - b. This mutation often occurs with IDH2 mutations
  - c. Patients with this mutation experience significant responses to IDH2 inhibitors
4. Which of the following drugs would be most appropriate for a patient with AML and an IDH1 mutation?
  - a. Ivosidenib
  - b. Enasidenib
  - c. Midostaurin
5. Which of the following statements is FALSE regarding the combination of liposomal daunorubicin and cytarabine for patients with AML?
  - a. It is FDA approved for patients with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes
  - b. It is associated with favorable survival outcomes when used as a bridge to transplant
  - c. It is poorly tolerated in most patients